{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-283328","form_type":"8-K","ticker":"CNVS","cik":"0001173204","company_name":"Cineverse Corp.","filed_at":"2025-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:38.928646+00:00","generated_at":"2026-05-16T19:45:09.605733+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Cineverse Q2 FY2026 net loss widens to $5.7M, revenue down 3% YoY","bullets":["Revenue $12.4M (down 3% YoY); Direct Operating Margin 58% (up 7pp).","Net loss $(5.7)M ($(0.31)/share) vs $(1.4)M ($(0.09)/share) a year ago.","Adjusted EBITDA $(3.7)M vs $0.5M prior; SG&A rose $5.0M to $11.4M on Toxic Avenger marketing and investments.","Cash $2.3M, $5.9M available on $12.5M credit line; net working capital $(1.3)M.","Content library valuation indication $45M vs book $3.2M; MicroCo venture and Matchpoint 3.0 launched."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-283328","json":"https://secwatch.observer/filing/0001193125-25-283328.json","markdown":"https://secwatch.observer/filing/0001193125-25-283328.md","text":"https://secwatch.observer/filing/0001193125-25-283328.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1173204/000119312525283328/0001193125-25-283328-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1173204/000119312525283328/cnvs-20251114.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T19:45:09.605733+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}